34th week of 2013 patent applcation highlights part 38 |
Patent application number | Title | Published |
20130216465 | POLYSILANES OF MEDIUM CHAIN LENGTH AND A METHOD FOR THE PRODUCTION OF SAME - Polysilanes of medium chain length as pure compounds or a mixture of compounds, each having at least one direct Si—Si bond, the substituents of the polysilanes consisting exclusively of halogen and/or hydrogen, the medium chain length n thereof being greater than 3 and smaller than 50, and the atomic ratio of substituent:silicon in the composition thereof being at least 1:1. | 2013-08-22 |
20130216466 | CHUNK POLYCRYSTALLINE SILICON AND PROCESS FOR CLEANING POLYCRYSTALLINE SILICON CHUNKS - The invention provides chunk polycrystalline silicon having a concentration of carbon at the surface of 0.5-35 ppbw. A process for cleaning polycrystalline silicon chunks having carbon contaminations at the surface, includes a thermal treatment of the polycrystalline silicon chunks in a reactor at a temperature of 350 to 600° C., the polycrystalline silicon chunks being present in an inert gas atmosphere during the thermal treatment, and the polycrystalline silicon chunks after the thermal treatment having a concentration of carbon at the surface of 0.5-35 ppbw. | 2013-08-22 |
20130216467 | METHOD OF PRODUCING SODA ASH AND CALCIUM CHLORIDE - The method of producing soda ash and calcium chloride provides an environmentally friendly method of producing soda ash and calcium chloride without the production of waste and hazardous byproducts. The method of producing soda ash and calcium chloride is initiated with a volume of brine, which is ammoniated with gaseous ammonia to form ammoniated brine. Limestone is heated to produce calcium oxide and carbon dioxide. The ammoniated brine is reacted with the carbon dioxide to produce sodium bicarbonate, ammonium chloride and a brine effluent. The sodium bicarbonate is then calcined and decomposed to produce soda ash and gaseous carbon dioxide. The calcium oxide is reacted with the ammonium chloride to produce calcium chloride, water and ammonia. The ammonia is recycled to be used in the initial step of ammoniating the brine. The water and the brine effluent are also recycled and used to provide the brine in the initial step. | 2013-08-22 |
20130216468 | METHOD AND APPARATUS FOR IN-LINE PRODUCTION OF MILK OF LIME INTO AN IN-LINE PRODUCTION PROCESS OF PCC ARRANGED IN CONNECTION WITH A FIBROUS WEB MACHINE - A method and apparatus for in-line production of milk of lime into an in-line production process of PCC arranged in connection with a fibrous web machine. In the solution, lime is slaked in a slaking apparatus at a temperature of at least 80 degrees. The produced milk of lime is cleaned by separating excessively large calcium hydroxide particles immediately prior to introducing the milk of lime into the production process of PCC. The milk of lime is introduced into the in-line production process of PCC located in the production line of the end or intermediate product of the fibrous web machine. | 2013-08-22 |
20130216469 | METHOD OF MANUFACTURING INFRARED SENSOR MATERIAL, INFRARED SENSOR MATERIAL, INFRARED SENSOR DEVICE AND INFRARED IMAGE SENSOR - A method of manufacturing an infrared sensor material includes preparing a CNT dispersion solution by dispersing a Carbon Nanotube (CNT) in a solvent, forming a CNT thin film using the CNT dispersion solution as a raw material, and annealing the CNT thin film so that an absolute value of the temperature coefficient of resistance is equal to or more than 1%/K at a temperature of −10° C. to 50° C. | 2013-08-22 |
20130216470 | CATALYST AND METHOD FOR THE PRODUCTION OF CHLORINE BY GAS PHASE OXIDATION - The present invention relates to a catalyst for preparation of chlorine by catalytic gas phase oxidation of hydrogen chloride with oxygen, in which the catalyst comprises calcined tin dioxide as a support and at least one halogen-containing ruthenium compound, and to the use thereof. | 2013-08-22 |
20130216471 | PROCESS FOR PREPARING CHROMIUM(III) OXIDE - The present invention relates to a process for preparing chromium(III) oxide by reaction of alkali metal chromate with gaseous ammonia, subsequent hydrolysis, isolation of the hydrolysis product and calcination. | 2013-08-22 |
20130216472 | GAS STORAGE MATERIAL AND METHOD FOR GAS STORAGE - The present invention relates to a gas storage material comprising a novel mesoporous polymer, that shows superior gas storage efficiency and can stably adsorb and desorb gas, and method for gas storage using thereof. | 2013-08-22 |
20130216473 | CATALYTIC FUEL VAPORIZER AND FUEL REFORMER ASSEMBLY - In one embodiment, an assembly for use with a lean NOx catalyst (LNC) is described. An outer tube is coupled to the LNC. An inner tube is disposed completely inside the outer tube. The exhaust flow is split between the inner tube and the outer tube. The inner tube houses a catalytic fuel vaporizer and a catalytic fuel reformer that convert at least a portion of the injected hydrocarbons to hydrogen and carbon monoxide, and vaporized hydrocarbons for NOx reduction. | 2013-08-22 |
20130216474 | NANOCELLS FOR DIAGNOSIS AND TREATMENT OF DISEASES AND DISORDERS - The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells may be size restricted such as being greater than about 60 nm so that they selectively extravasate at sites of angiogenesis (e.g. tumor) and do not pass through normal vasculature or enter non-tumor bearing tissue. In this way, angiogenic sites can be both detected and treated. In another embodiment, nanocells are tailored for various treatment methods, including the treatment of brain cancer, asthma, Grave's Disease, Cystic Fibrosis, and Pulmonary Fibrosis. | 2013-08-22 |
20130216475 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING - A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce | 2013-08-22 |
20130216476 | USE OF AN ANTI-CD71 ANTIBODY FOR PREPARING A MEDICAMENT - The use of an anti-CD71 monoclonal antibody or a fragment of an abovementioned antibody capable of binding to the CD71 antigen for the preparation of a drug intended for the prevention or treatment of myelomas. | 2013-08-22 |
20130216477 | METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX - The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. | 2013-08-22 |
20130216478 | Non-Invasive Diagnostic Agents of Cancer and Methods of Diagnosing Cancer, Especially Leukemia and Lymphoma - The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. | 2013-08-22 |
20130216479 | SITE-SPECIFIC CHEMICAL MODIFICATION OF PROTEINS AT THEIR N-TERMINI, ENABLING THE FORMATION OF HOMOGENEOUS ADDUCTS - Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of disorders such as cancer, Crohn's disease, arthritis, atherothrombosis and plaque rupture are also provided. | 2013-08-22 |
20130216480 | AMPHIPHILIC POLYMERS AND METHODS OF USE THEREOF - The present invention relates to amphiphilic polymers, and micelles and compositions comprising the same, and their use in a variety of biological settings, including imaging, targeting drugs, or a combination thereof for diagnostic and therapeutic purposes. | 2013-08-22 |
20130216481 | USE OF UTP FOR THE DIAGNOSIS OF STENOSES AND OTHER CONDITIONS OF RESTRICTED BLOOD FLOW - The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively in the vessel by obtaining a value that correlates to blood flow in said vessel, comparing the obtained value with a reference value, and determining whether the individual has compromised blood flow based on the results of the comparison. The invention also provides for methods of diagnosing atherosclerotic and ischemic heart diseases using UTP, a derivative thereof, or a salt thereof, as well as methods for inducing maximal hyperemia for diagnostic purposes. | 2013-08-22 |
20130216482 | METHODS AND COMPOSITIONS FOR NON-INVASIVE, DYNAMIC IMAGING OF INTESTINAL MOTILITY - Described are methods and composition for use in non-invasive imaging of intestinal structure and function. These methods can be used to identify, diagnose, assess, monitor and direct therapies for gastrointestinal diseases and disorders. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye excreted in bile into the intestinal tract to provide quantitative information regarding intestinal propulsion and function. | 2013-08-22 |
20130216483 | DELIVERY SYSTEM FOR REMOTE TREATMENT OF AN ANIMAL - A method of remotely treating an animal including launching a delivery system at the animal, wherein the delivery system comprises a dosage projectile adapted to deliver a biologically active agent to an animal substantially without piercing the skin of the animal and containing a biologically active agent and a transdermal carrier in liquid or gel form, wherein the agent and the carrier are encapsulated in one or more encapsulating agents, and wherein the encapsulating agents forms a frangible shell; impacting the projectile on the animal to release the biologically active agent and the transdermal carrier from the frangible shell substantially without piercing the skin of the animal; and delivering the biologically active agent to the animal, wherein the transdermal carrier facilitates passage of the biologically active agent across the skin of the animal to provide treatment to the animal. | 2013-08-22 |
20130216484 | BIOENZYMATIC TABLET - It is contemplated that the tablet of the present invention is primarily utilized cleaning of dental instruments. In application a receptacle, such as sonic cleansing machine, is provided with a supply of water. An effervescent tablet containing a bioenzymatic compound is introduced to the water to create a cleaning solution. Soiled dental equipment may be placed in the cleaning solution and the bioenzymatics present in the tablet identify the nature of the waste present on the soiled instruments and begin to produce the enzymes necessary to breakdown the waste thereby cleaning the instruments. | 2013-08-22 |
20130216485 | Dentifrice Composition with Reduced Astringency - A dentifrice composition containing, in combination, an orally acceptable vehicle; a halogenated diphenyl ether; a soluble zinc salt; and a chelating agent to reduce astringency. | 2013-08-22 |
20130216486 | SYNTHESIS OF CYCLOHEXANE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS - The present invention provides synthetic routes for preparing various isomers of cyclohexane-based coolants, such as menthyl esters and menthanecarboxamide derivatives, in particular those substituted at the amide nitrogen, for example with an aromatic ring or aryl moiety. Such structures have high cooling potency and long lasting sensory effect, which make them useful in a wide variety of consumer products. One synthetic route involves a copper catalyzed coupling of a primary menthanecarboxamide with an aryl halide, such reaction working best in the presence of potassium phosphate and water. Using this synthetic route, specific isomers can be prepared including the menthanecarboxamide isomer having the same configuration as l-menthol and new isomers such as a neoisomer having opposite stereochemistry at the carboxamide (C-1) position. The neoisomer unexpectedly has potent and long lasting cooling effect. Preparation schemes for neoisomers of other menthyl derivatives which are useful as coolants, including esters, ethers, carboxy esters and other N-substituted carboxamides are also provided. | 2013-08-22 |
20130216487 | Teeth-Whitening Gel - A teeth-whitening gel is provided. The main ingredient of the teeth-whitening gel comprises a polypeptide having halamine (N—X bond, X═Cl, Br or I) groups and a high molecular weight. By the redox properties of halamine group, the gel contacting with the teeth's surface can bleach and whiten the teeth. | 2013-08-22 |
20130216488 | ANTIMICROBIAL, ANTIBACTERIAL AND SPORE GERMINATION INHIBITING ACTIVITY FROM AN AVOCADO EXTRACT ENRICHED IN BIOACTIVE COMPOUNDS - The present disclosure relates to extracts from | 2013-08-22 |
20130216489 | Polysaccharide Products With Improved Performance And Clarity In Phosphate Ester Surfactant-Based Aqueous Formulations And Process For Preparation - A personal or household care product includes cationic, nonionic or cationic/nonionic derivatized polysaccharide in combination with a phosphate ester surfactant. The derivatized polysaccharide polymer is formed by reacting the polysaccharide ester surfactant for a sufficient time and at a sufficient temperature in the presence of water, caustic, and at least one surfactant. The polysaccharide polymer may optionally be reacted with an oxidizing agent, hydrolytic or proteolytic enzymes, molecular weight reducing agents and a cationizing agent and nonionic agent. The formed derivatized polysaccharide has a lower clarity in water than in an aqueous surfactant system. | 2013-08-22 |
20130216490 | HAIR TREATMENT AGENTS HAVING LOW-DOSE OLIGOPEPTIDES - A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to ≦0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), | 2013-08-22 |
20130216491 | COMPOSITION FOR CLEANING SCALP AND HEAD HAIR - This invention provides a cleaning composition comprising a certain amount or more of an acylamino acid type surfactant, and further a non-ionic surfactant and a betaine-type ampholytic surfactant, which has a sufficient viscosity and exerts excellent conditioning effects. | 2013-08-22 |
20130216492 | Method for Searching for Malodor Control Agent, Malodor Control Agent, and Malodor Control Method - Provided are a method for searching for a malodor inhibitor by using the response of an olfactory receptor as an indicator; a method for inhibiting malodor based on the antagonism of olfactory receptors; and a malodor inhibitor. Disclosed are a method for searching for a malodor inhibitor, the method including: adding a test substance and a malodor-causing substance to any one olfactory receptor selected from the group consisting of OR51E1, OR2W1, OR10A6, OR51I2, and OR51L1, measuring the response of the olfactory receptor to the malodor-causing substance, identifying the test substance that suppresses the response of the olfactory receptor on the basis of the measured response, and selecting the identified test substance as a malodor inhibitor; an antagonist to any one olfactory receptor selected from the group consisting of OR51E1, OR2W1, OR10A6, OR51I2, and OR51L1; a method for inhibiting malodor using the antagonist. | 2013-08-22 |
20130216493 | PEG OR PEG BLOCK COPOLYMERS FOR TREATING COLORECTAL CANCER - The present invention relates to methods for and of treating, ameliorating or preventing colorectal cancer (CRC) in humans using polyethylene glycol (PEG) or a PEG block-copolymer such as Pluronic® F68. Compositions for use in treating, ameliorating and/or preventing CRC comprising PEG are also disclosed. Such compositions may be used in the methods of the invention. | 2013-08-22 |
20130216494 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof - One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. | 2013-08-22 |
20130216495 | PHARMACEUTICAL COMPOSITION COMPRISING CD34+ CELLS - The invention relates to the field of treatment of ischemic conditions and diseases using a cell population comprising CD34+ cells isolated from peripheral blood of a subject. The invention provides a pharmaceutical composition comprising (i) a cell population comprising CD34+ cells, (ii) a plasma protein, and (iii) an isotonic solution comprising at least one salt, said isotonic solution comprising acetate, gluconate, or both acetate and gluconate. Methods of treating tissue damaged by ischemia in a subject and methods of treating a medical condition, wherein the pharmaceutical composition of the invention is administered, are further provided herein. Also, methods of promoting mobilization of CD34+ cells from bone marrow into peripheral blood are provided herein. | 2013-08-22 |
20130216496 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 2013-08-22 |
20130216497 | NOVEL TRICYCLIC COMPOUNDS - The invention provides compounds of Formula (I) and Formula (II) | 2013-08-22 |
20130216498 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS - New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). | 2013-08-22 |
20130216499 | COMPOSITIONS OF RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS INJECTIONS AND METHODS OF PRODUCTION - The invention generally relates to compositions of and methods for production of recombinant adenoviruses that carry therapeutic genes. More particularly, the invention relates to lyophilized recombinant adenoviruses injection and its related production procedures, including production procedures for the recombinant adenovirus vectors (or other viral vectors) that carry the genes of human endostatins. | 2013-08-22 |
20130216500 | METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS - A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method. | 2013-08-22 |
20130216501 | THERAPEUTIC METHODS BASED ON TYROSINE-SUBSTITUTED, CAPSID-MODIFIED RAAV VECTORS - Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors. | 2013-08-22 |
20130216502 | Methods of Treating Intestinal Injury Using Heparin Binding Epidermal Growth Factor and Stem Cells - The invention provides for methods of treating, abating and reducing the risk for intestinal injury by administering a combination heparin binding epidermal growth factor (HB-EGF) and stem cells, such as mesenchymal stem cells or intestinal stem cells, in an amount effective to reduce the onset or severity of intestinal injury. The invention also provides for methods of promoting engraftment of stem cells, such as mesenchymal stem cells or intestinal stem cells, within the intestine of a patient suffering from intestinal injury. | 2013-08-22 |
20130216503 | Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes. | 2013-08-22 |
20130216504 | CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTEC USES - The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof. | 2013-08-22 |
20130216505 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF AN ALLOGENIC CELL AND THERAPEUTIC USES - Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. | 2013-08-22 |
20130216506 | Bioreactor for Isolation of Rare Cells and Methods of Use - The present invention relates to a bioreactor apparatus, and methods of use, for the isolation of rare blood cells, including hematopoietic stem cells and megakaryocytes. The apparatus includes a soft substrate and an anti-contractility agent, thereby providing a soft microenvironment to cultured cells. The apparatus of the invention is permissive for the survival of non-dividing cells while dividing cells are eliminated. This unique property allows for the simple isolation of rare blood cells without the use of costly equipment and antibodies. | 2013-08-22 |
20130216507 | METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 2013-08-22 |
20130216508 | HUMAN LUNG STEM CELLS AND USES THEREOF - Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases. | 2013-08-22 |
20130216509 | CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. | 2013-08-22 |
20130216510 | Probiotic Strains for Use in Improving Transepithelial Resistance - The invention relates to the use of lactic acid bacteria, for use in improving transepithelial resistance and more particularly in treating and/or preventing constipation and/or irritable bowel disease. | 2013-08-22 |
20130216511 | BACILLUS SUBTILIS ISOLATE FROM CORN - Biologically pure cultures of | 2013-08-22 |
20130216512 | STABLE AQUEOUS SUSPENSION - An aqueous suspension of a hydrophobic nutrient is disclosed, in particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension. | 2013-08-22 |
20130216513 | Chimeric Clotting Factors - Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasia using these clotting factors. | 2013-08-22 |
20130216514 | COMPOSITIONS COMPRISING GLUTATHIONE REDUCTASE AND OXIDIZED GLUTATHIONE - Compositions comprising Glutathione Reductase (GSSG-r) and Oxidized Glutathione (GSSG) or pharmaceutically acceptable salts thereof for pharmaceutical use as antiviral and antibacterial agents and for the protection against the toxicity of free radicals and in particular radicals produced by the radiolysis of cellular water are provided. Methods of making and using such compositions are also provided. | 2013-08-22 |
20130216515 | PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions. | 2013-08-22 |
20130216516 | METHOD FOR TREATING DELAYED-TYPE HYPERSENSITIVITY - The invention is directed to treatment of delayed-type hypersensitivity reactions associated with changes of qualitative and/or quantitative composition of blood extracellular DNA and treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 2013-08-22 |
20130216517 | STANDARDIZED BEE VENOM PREPARATION - Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic dramatically decreased pain and discomfort for patients undergoing apitherapy. | 2013-08-22 |
20130216518 | COMPOSITION COMPRISING A COMBINATION OF AT LEAST ONE PROTEOLYTIC ENZYME AND AT LEAST ONE LIPOLYTIC ENZYME, FOR USE IN PREVENTING TRIGLYCERIDE SYNTHESIS - The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use as a drug, cosmetic agent, medical device, dietary composition, dietary supplement or nutraceutical, notably for use in preventing or treating obesity, atherosclerosis, type 2 diabetes or for use in preventing or reducing excess weight. | 2013-08-22 |
20130216519 | PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME - The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins. | 2013-08-22 |
20130216520 | PROCESSING BIOMASS - Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids. | 2013-08-22 |
20130216521 | DIETARY SUPPLEMENT FOR ENHANCING ANIMAL HEALTH - A dietary supplement system including three general components is provided. The first component is the fatty acid component and this includes sunflower seeds (containing omega 6 fatty acids), flax seed (containing omega 3 fatty acids) and powdered oils (containing omega 3 or omega 6 fatty acids and generally produced from sunflower oils). The weight ratio of omega 6 fatty acids to omega 3 fatty acids is 10:1 to 1:1, with 10:1 to 5:1 being preferred for normal animals and 2:1 to 1:1 being preferred for animals which have fatty acid responsive conditions. The second component is the GI component, which is used for facilitating animal gut health. This component includes prebiotics, probiotics and immunoglobulin (typically from albumin concentrate). The third component is the breed specific component and can include vitamins, minerals, additional fatty acids, antioxidants, amino acids, palatants, and nutraceutical additives. | 2013-08-22 |
20130216522 | STABILIZED HUMAN IMMUNOGLOBULIN COMPOSITION - The invention relates to a liquid pharmaceutical composition comprising human immunoglobulins G (IgGs), comprising at least 200 mM, preferably 250 mM±50 mM, of glycine and between 20 and 100 mg/l of a non-ionic detergent, and having a pH of less than or equal to 4.8. | 2013-08-22 |
20130216523 | Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression - Methods are provided for facilitating the diagnosis of subjects with HER1-activated cancers. In addition, method of treating subjects with a cancer characterized as having high levels of activated HER1 are provided. Also provided are methods for determining or otherwise assessing the prognosis of an subject with a HER1-activated cancer. The methods include the analysis of samples for the presence or the absence of activated HER1 markers as indicated by HER1-HER1 homodimers, HER1 phosphorylation at position 1173, pan-phosphorylation of HER1 or associated molecules, or HER1-HER2 heterodimers. Activated HER1 measurements can be used to track a subject's response to a treatment regimen, predict the success of using a particular treatment regimen, determine the effects of a treatment regimen, or for categorizing a subject in order to create a homogenous group for a clinical trial. | 2013-08-22 |
20130216524 | Predictors for Cancer Treatment - The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMB1 (P11A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer. | 2013-08-22 |
20130216525 | CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF - Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody, to a subject who is afflicted with a disease or condition that is treatable by the protein drug. | 2013-08-22 |
20130216526 | METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS - This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log | 2013-08-22 |
20130216527 | NOVEL ANTI-CMET ANTIBODY - The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met. The invention finally comprises products and/or compositions comprising such an antibody in combination with other antibodies and/or chemical compounds directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 2013-08-22 |
20130216528 | Anti-GD2 Antibodies - In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma. | 2013-08-22 |
20130216529 | HUMANEERED ANTI-FACTOR B ANTIBODY - This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof. | 2013-08-22 |
20130216530 | Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants - The invention provides methods for treating humans in need of combined immunosuppressant and biological response modifier therapy. | 2013-08-22 |
20130216531 | ANTI-CXCR4 AS A SENSITIZER TO CANCER THERAPEUTICS - Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy. | 2013-08-22 |
20130216532 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 2013-08-22 |
20130216533 | BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2013-08-22 |
20130216534 | USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS - The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors. | 2013-08-22 |
20130216535 | ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME - The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. | 2013-08-22 |
20130216536 | INHIBITORS OF EXTRACELLULAR HSP90 - The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells. | 2013-08-22 |
20130216537 | Methods of Treating Glucose Metabolism Disorders and Promoting Weight Loss - Compositions and methods for treating individuals with a glucose metabolism disorder and methods for promoting weight loss in an individual are provided. | 2013-08-22 |
20130216538 | Compositions and Methods for Treating Inflammatory Disorders - The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders. | 2013-08-22 |
20130216539 | Methods of Generation and Treatment with Modified Derivatives of HSP 70 - The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins. | 2013-08-22 |
20130216540 | MODULATION OF THE INNATE IMMUNE SYSTEM THROUGH THE TREM-LIKE TRANSCRIPT 2 PROTEIN - TREM-like transcript 2 (TLT2), is expressed on neutrophils, macrophages, and B lymphocytes. Expression of TLT2 is up-regulated on neutrophils and macrophages in response to inflammatory stimuli in vivo and synergizes with agonists that bind to G-protein coupled receptors (GPCR) to potentiate the neutrophil antibacterial and chemotactic response. Administration of anti-TLT2 mAb enhances the acute inflammatory response in vivo that is associated with increased neutrophil recruitment to sites of inflammation. TLT2 ligation in vivo also potentiates chemokine and growth factor production indicating that TLT2 can exert both neutrophil intrinsic and extrinsic effects. The administration of anti-TLT2 mAb alone promotes neutrophil recruitment to the lung and peritoneum, as well as the rapid production of G-CSF, CXCL1 (KC) and CXCL2 (MIP-2). Additionally, the administration of an agent to the circulatory system of an animal can reduce the availability of a TLT2 endogenous ligand to reduce the extent of a neutrophil or macrophage-induced inflammatory response. | 2013-08-22 |
20130216541 | STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF - The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction. | 2013-08-22 |
20130216542 | VARIABLE REGION SEQUENCES OF IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USE - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions. | 2013-08-22 |
20130216543 | ANTIBODY-BASED CONSTRUCTS DIRECTED AGAINST TYROSINE KINASE RECEPTORS - The present invention features antibody-based constructs that include a combination of two or more of a tetrameric antibody, a single chain antibody, a diabody, a triabody, another immunoglobulin-based moiety, as described herein, or biologically active variants thereof. | 2013-08-22 |
20130216544 | Anti-La antibodies and their use for immunotargeting - The invention relates to antibodies against the human La protein and to their use in immunotargeting, in particular the immunotargeting of tumour cells. The object of the invention is to provide improved antibodies which bind universal target structures on the surface of tumour cells, and to provide novel anti-La antibodies, in particular with a high affinity for La, a universal target structure on tumour cells, which make it possible to use the antibodies as recombinant fragments for immunotargeting. The invention comprises recombinant antibodies comprising: i. a binding unit of an antibody which specifically binds to an epitope of a human nuclear antigen, preferably human La protein, and ii. a binding unit of an antibody which specifically binds to an effector cell or of a ligand which specifically binds to an effector cell. The invention furthermore comprises novel antibodies which specifically bind the human La protein. | 2013-08-22 |
20130216545 | Early Diagnosis and Novel Treatment of Cancer - The present invention relates to novel therapies for treatment and new biomarkers for earlier detection of pancreatic and other cancers. In particular, the present invention identifies Reg1α and Reg3α, and other members of the Reg protein family, as signaling proteins for a receptor on the surface of human cancer cells, Megi, and the downstream pathways activated through this receptor in pancreatic and other tumor cells. These signaling proteins may be targeted by means known in the art to disrupt the downstream signaling pathway that catalyzes tumorigenesis, by the usage of antibodies, antisense, RNA interference, small molecule inhibitors and vaccines. | 2013-08-22 |
20130216546 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions suitable for use in the methods, are provided. | 2013-08-22 |
20130216547 | ANTI-BIG-ENDOTHELIN-1 (BIG-ET-1) ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind big-endothelin-1 (“big-ET-1”), and methods of using same. According to certain embodiments of the invention, the antibodies specifically bind human big-ET-1 but do not bind human small-ET-1 (i.e., the active form of endothelin-1 that results from proteolytic cleavage of big-ET-1 by endothelin-converting enzyme-1 [ECE-1]). According to certain embodiments of the invention, the anti-big-ET-1 antibodies are capable of blocking cleavage of big-ET-1 by ECE-1. The antibodies of the invention are useful for the treatment of big-ET-1-related disorders, including hypertension disorders, fibrotic disorders, neurodegenerative disorders, retinal disorders, pain and cancers. | 2013-08-22 |
20130216548 | MONOCLONAL ANTIBODIES AGAINST C-MET - Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed. | 2013-08-22 |
20130216549 | Anti-IP-10 Antibodies and Uses Thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder. | 2013-08-22 |
20130216550 | BREAST CANCER THERAPEUTICS - The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient. | 2013-08-22 |
20130216551 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHDOS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2013-08-22 |
20130216552 | CRTH2 MODULATORS - Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed herein. The compounds are described by structural Formula I: | 2013-08-22 |
20130216553 | Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses - A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison is indicative of the inflammatory or the autoimmune condition. An example of the autoimmune condition is multiple sclerosis. According to one embodiment, an increased ratio of phosphoglycerol dihydroceramide (PG DHC) to phosphoethanolamine dihydroceramide (PE DHC) in a blood sample indicates a presence of MS in the source patient. The use of PDHCs as biomarkers for detection of MS is described. Antibodies specific to PG DHC or PE DHC are also provided, along with their uses. Also provided are compositions comprising bacteria-originated lipids useful for modulation of immune responses or TLR pathways in humans, animals, and human or animal cells or tissues. | 2013-08-22 |
20130216554 | Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin - Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof. | 2013-08-22 |
20130216555 | METHOD OF PROVIDING DISEASE-SPECIFIC BINDING MOLECULES AND TARGETS - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 2013-08-22 |
20130216556 | ANTIBODY FORMULATIONS - Formulations of anti-VLA-1 antibodies are described. | 2013-08-22 |
20130216557 | LTBR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS - The invention provides compositions and methods for predicting therapeutic responsiveness of a subject having an autoimmune disorder to an agent that inhibits signaling via LTβR based on the level of expression of IFN or a marker thereof in the subject. The invention also provides methods of treating selected subjects with agents that inhibit or reduce signaling vial LTβR. | 2013-08-22 |
20130216558 | COMPOSITIONS AND METHODS FOR TREATING HAEMATOLOGICAL PROLIFERATIVE DISORDERS OF MYELOID ORIGIN - The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells. | 2013-08-22 |
20130216559 | Stromal Antigen 2 (STAG2) Compositions and Methods - Compositions and methods related to stromal antigen 2 (STAG2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines. | 2013-08-22 |
20130216560 | Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 2013-08-22 |
20130216561 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate. | 2013-08-22 |
20130216562 | PRODUCTION OF CLOSED LINEAR DNA USING A PALINDROMIC SEQUENCE - A primer for the amplification of a DNA template comprising a protelomerase target sequence, particularly for production of closed linear DNA, which primer is capable of specifically binding to a palindromic sequence within a protelomerase target sequence and priming amplification in both directions. | 2013-08-22 |
20130216563 | Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof - The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed. | 2013-08-22 |
20130216564 | Immunogenic Epitopes, Peptidomimetics, And Anti-Peptide Antibodies, And Methods of Their Use - Provided herein are compositions and methods for the treatment of cancers. The compositions comprise at least one VEGF peptide mimic, HER-2 epitope, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. The peptides and epitopes may be linear, cyclized, retro-inverso, or a combination of such forms. Also provided herein are antibodies raised to VEGF peptide mimics, HER-2 epitopes, immunogenic VEGF peptides, and HER-2 immunogenic epitopes. | 2013-08-22 |